Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment - Poordad, Fred; Felizarta, Franco; Asatryan, Armen; Sulkowski, Mark S.; Reindollar, Robert W.; Landis, Charles S.; Gordon, Stuart C.; Flamm, Steven L.; Fried, Michael W.; Bernstein, David E.; Lin, Chih‐Wei; Liu, Ran; et al. (Hepatology (Baltimore, Md.), 2017)
Keywords: Administration, Oral; Adolescent; Adult; Aged; Alanine; Alanine transaminase; Aminoisobutyric Acids; Antiretroviral drugs; Antiviral Agents - therapeutic use; Antiviral drugs; Benzimidazoles - therapeutic use; Bilirubin; Chronic infection; Cirrhosis; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Genotype & phenotype; Hemoglobin; Hepacivirus - genetics; Hepatitis; Hepatitis C; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - drug therapy; Hepatology; Humans; Infections; Interferon; Interferon-alpha - therapeutic use; Lactams, Macrocyclic; Leucine - analogs & derivatives; Liver cirrhosis; Liver Function Tests; Male; Middle Aged; Original; Proline - analogs & derivatives; Pyrrolidines; Quinoxalines - therapeutic use; Retreatment; Ribavirin; Ribavirin - therapeutic use; Sulfonamides - therapeutic use; Time Factors; Treatment Outcome; United States; Viral Load - drug effects; Young Adult; United States